A retrospective real world study evaluating efficacy and safety of switching from Innovator Infliximab to Biosimilar CT-P13 in patients with inflammatory rheumatic disease

Trial Profile

A retrospective real world study evaluating efficacy and safety of switching from Innovator Infliximab to Biosimilar CT-P13 in patients with inflammatory rheumatic disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Rheumatic disorders
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Jul 2017 New trial record
    • 30 Jun 2017 Results published in the Drugs in R and D
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top